MyMD Pharmaceuticals Inc. (NASDAQ:MYMD) finished Friday with an addition of $0.25 to close at $1.44, an upside of 21.01 percent. An average of 648,300 shares of common stock have been traded in the last five days. There was a fall of -$0.2600 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,226,220 shares traded, while the 50-day average volume stands at 775,480.
MYMD stock has increased by 60.20% in the last month. The company shares reached their 1-month lowest point of $0.8000 on 07/17/23. With the stock rallying to its 52-week high on 02/02/23, shares of the company touched a low of $0.80 and a high of $5.30 in 52 weeks. It has reached a new high 9 times so far this year and achieved 25.22% or $0.2900 in price. In spite of this, the price is down -72.86% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
MyMD Pharmaceuticals Inc. (MYMD) stock’s beta is 2.19. Other valuation ratios to consider include the price-to-book (PB) ratio at 4.36.
Financial Health
The quick ratio of MyMD Pharmaceuticals Inc. for the recent quarter was 10.00, and the current ratio was 10.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the recent quarter.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, MyMD Pharmaceuticals Inc.’s return on assets was -59.70%.
Earnings Surprise
For the recent quarter, MyMD Pharmaceuticals Inc. had $15.36 million in cash. The company posted a net income of -$1.67 million in the quarter, while revenues of -$3.75 million were shrunk -146.71%. Shareholders own equity worth $39.6 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at MyMD Pharmaceuticals Inc. (MYMD) price momentum. RSI 9-day as of the close on 11 August was 53.60%, suggesting the stock is Neutral, with historical volatility in this time frame at 228.29%.
As of today, MYMD’s price is $1.3340 -15.29% or -$0.2600 from its 5-day moving average. MYMD is currently trading +79.98% higher than its 20-day SMA and -24.21% lower than its 100-day SMA. However, the stock’s current price level is -17.24% below the SMA50 and -41.94% below the SMA200.
The stochastic %K and %D were 27.87% and 30.41%, respectively, and the average true range (ATR) was 0.2175. With the 14-day stochastic at 36.70% and the average true range at 0.2027, the RSI (14) stands at 52.57%. The stock has reached -0.2122 on the 9-day MACD Oscillator while the 14-day reading was at -0.1021.
Analyst Ratings
The consensus rating for MyMD Pharmaceuticals Inc. (MYMD) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell MYMD, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is MYMD’s price target for the next 12 months?
Analysts predict a range of price targets between $1536.00 and $1536.00, with a median target of $1536.00. Taking a look at these predictions, the average price target given by analysts for MyMD Pharmaceuticals Inc. (MYMD) stock is $1536.00.
